2-Aminopyridine

2-Aminopyridine

SCHEMBL667672

NC(=O)c1nccc(N)n1.Nc1ccccn1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.53
NOS1 P29475 1/20 0.53
NOS2 P35228 1/20 0.53
PI4KA P42356 1/20 0.53
PI4K2B Q8TCG2 1/20 0.53
PI4K2A Q9BTU6 1/20 0.53
PI4KB Q9UBF8 1/20 0.53
MKNK1 Q9BUB5 2/20 0.38
MKNK2 Q9HBH9 2/20 0.38
NNMT P40261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PARP1 P09874 1/20 0.37
CDC7 O00311 3/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669901 0.88 MKNK1 (0.42) MKNK1MKNK2NNMTSMN1; SMN2PARP1
2-Aminopyridine SCHEMBL28327874 0.80 NOS3 (0.76) NOS3NOS1NOS2PI4KAPI4K2B
2-Aminopyridine SCHEMBL5693366 0.78 NOS3 (0.73) NOS3NOS1NOS2PI4KAPI4K2B
2-Aminopyridine SCHEMBL2221610 0.76 NOS3 (0.70) NOS3NOS1NOS2PI4KAPI4K2B
2-Aminopyridine SCHEMBL2152741 0.76 NOS3 (0.76) NOS3NOS1NOS2PI4KAPI4K2B
2-Aminopyridine SCHEMBL1657384 0.75
2-Aminopyridine SCHEMBL29465204 0.75
2-Aminopyridine SCHEMBL8135890 0.75 NOS3 (0.94) NOS3NOS1NOS2PI4KAPI4K2B
2-Aminopyridine SCHEMBL2859676 0.75
Benzamide SCHEMBL28292769 0.75 L3MBTL1 (0.61) NOS3NOS1NOS2PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2013536234-A 2013-09-19 JP disclosed
EP-2608672-A1 AMINOPYRIDINE- AND AMINOPYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS Syntrix Biosystems, Inc. (US) 2013-07-03 EP disclosed
WO-2012027289-A1 AMINOPYRIDINE- AND AMINOPYRIMIDINECARBOXAMIDES AS CXCR2 MODULATORS SYNTRIX BIOSYSTEMS INC. (US) 2012-03-01 WO disclosed
US-20120046243-A1 Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators SYNTRIX BIOSYSTEMS INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046243-A1 Aminopyridine- and Aminopyrimidinecarboxamides as CXCR2 Modulators CXCR2, CXCR5, CXCR3 NOS3 2812/4885NOS1 2329/4885NOS2 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.